Melissa L Larson

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi HIV-related lymphoma treated with maintenance thalidomide
    Melissa L Larson
    Rush University Medical Center, Chicago, IL 60612, USA
    Clin Adv Hematol Oncol 3:231-4; discussion 234-5. 2005
  2. ncbi Clofarabine: a new treatment option for patients with acute myeloid leukemia
    Melissa L Larson
    Section of Hemtology, Rush University Medical Center, 1725 West Harrison, Suite 809, Chicago, IL 60612, USA
    Expert Opin Pharmacother 10:1353-7. 2009
  3. ncbi Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lym
    Reem Karmali
    Rush University Medical Center, Department of Hematology Oncology, Chicago, IL 60612, USA
    Leuk Lymphoma 52:2097-104. 2011
  4. ncbi Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients
    Reem Karmali
    Division of Hematology Oncology Cell Therapy, Rush University Medical Center, 1725 W Harrison St, Chicago, IL 60612, USA
    J Leukoc Biol 93:161-70. 2013
  5. ncbi Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation
    Justin M Goldfarb
    Section of Hematology and Oncology, Rush University Medical Center, Chicago, IL 60612, USA
    Clin Adv Hematol Oncol 4:600-4; discussion 604-6. 2006

Collaborators

Detail Information

Publications5

  1. ncbi HIV-related lymphoma treated with maintenance thalidomide
    Melissa L Larson
    Rush University Medical Center, Chicago, IL 60612, USA
    Clin Adv Hematol Oncol 3:231-4; discussion 234-5. 2005
  2. ncbi Clofarabine: a new treatment option for patients with acute myeloid leukemia
    Melissa L Larson
    Section of Hemtology, Rush University Medical Center, 1725 West Harrison, Suite 809, Chicago, IL 60612, USA
    Expert Opin Pharmacother 10:1353-7. 2009
    ..This compound seems to have efficacy in older patients, as well as those with adverse cytogenetics...
  3. ncbi Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lym
    Reem Karmali
    Rush University Medical Center, Department of Hematology Oncology, Chicago, IL 60612, USA
    Leuk Lymphoma 52:2097-104. 2011
    ..The most common toxicity was myelosuppression. Sequential combination of CHOP with GM-CSF priming and rituximab was feasible and effective, warranting further evaluation...
  4. ncbi Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients
    Reem Karmali
    Division of Hematology Oncology Cell Therapy, Rush University Medical Center, 1725 W Harrison St, Chicago, IL 60612, USA
    J Leukoc Biol 93:161-70. 2013
    ..This suggests utility in detecting disease progression early, identifying those likely to incur a survival advantage with early treatment, and directing future therapy...
  5. ncbi Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation
    Justin M Goldfarb
    Section of Hematology and Oncology, Rush University Medical Center, Chicago, IL 60612, USA
    Clin Adv Hematol Oncol 4:600-4; discussion 604-6. 2006